Validation and epidemiologic definition of the novel steatotic liver disease nomenclature in a national United States cohort with cirrhosis

Hepatology

Prevalence of metabolic dysfunction-associated steatotic liver disease and fibrosis defined by liver elastography in the United States using National Health and Nutrition examination survey 2017-march 2020 and august 2021-august 2023 data

Hepatology

Unalp-Arida A, Ruhl CE

doi: 10.1097/HEP.0000000000001211

Hepatology

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study : MASLD, MetALD, and dementia risk

BMC Gastroenterol

Shin WY, Kang ES, Oh YH, Sha M, Xia Q, Jeong S, Cho Y

doi: 10.1186/s12876-025-03814-1

Hepatology

Epidemiology of compensated Advanced Chronic Liver Disease (cACLD) in the United States: Insights from NHANES 2017-2020

Clin Gastroenterol Hepatol

Goyal RM, Doshi A, Rao S, Arora K, Maheshwari S, Gaglio P

doi: 10.1016/j.cgh.2025.06.010

HepatologyFurther Publications

GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

JAMA Intern Med

Kanwal F, Kramer JR, Li L, Yang YX, Cao Y, Yu X, Samuel R, Ali B, Desiderio R, Cholankeril G, Bajaj M, El-Serag HB, Asch SM

doi: 10.1001/jamainternmed.2024.4661

Further Publications

Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2024

Gastroenterology

Peery AF, Murphy CC, Anderson C, Jensen ET, Deutsch-Link S, Egberg MD, Lund JL, Subramaniam D, Dellon ES, Sperber AD, Palsson OS, Pate V, Baron TH, Moon AM, Shaheen NJ, Sandler RS

doi: 10.1053/j.gastro.2024.12.029

Hepatology

Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA

Gut

Yang AH, Tincopa MA, Tavaglione F, Ajmera VH, Richards LM, Amangurbanova M, Butcher C, Hernandez C, Madamba E, Singh S, Bettencourt R, Schnabl B, Sirlin CB, Loomba R

doi: 10.1136/gutjnl-2024-332917

Hepatology

Optimal population screening strategies for liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease

Am J Gastroenterol

Kim WR, Mannalithara A, Charu V, Chung N, Kwong A, Kwo PY, Torok NJ, Asch SM, Kim SH

doi: 10.14309/ajg.0000000000003268

Hepatology

The liver-brain axis in metabolic dysfunction-associated steatotic liver disease

Lancet Gastroenterol Hepatol

Mikkelsen ACD, Kjærgaard K, Schapira AHV, Mookerjee RP, Thomsen KL

doi: 10.1016/S2468-1253(24)00320-0

Hepatology

Non-invasive assessment of severe liver fibrosis in patients with Fontan-associated liver disease: The VALDIG-EASL FONLIVER cohort

J Hepatol

Téllez L, Rincón D, Payancé A, Jaillais A, Lebray P, Rodríguez de Santiago E, Clemente A, Paradis V, Lefort B, Garrido-Lestache E, Prieto R, Iserin L, Tallegas M, Garrido E, Torres M, Muriel A, Perna C, Jesús Del Cerro M, d'Alteroche L, Rautou PE, Bañares R, Albillos A, VALDIG-EASL consortium

doi: 10.1016/j.jhep.2024.09.005

Related content

Prevalence of metabolic dysfunction-associated steatotic liver disease and fibrosis defined by liver elastography in the United States using National Health and Nutrition examination survey 2017-march 2020 and august 2021-august 2023 data

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study : MASLD, MetALD, and dementia risk

Epidemiology of compensated Advanced Chronic Liver Disease (cACLD) in the United States: Insights from NHANES 2017-2020

GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2024

Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA

Optimal population screening strategies for liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease

The liver-brain axis in metabolic dysfunction-associated steatotic liver disease

Non-invasive assessment of severe liver fibrosis in patients with Fontan-associated liver disease: The VALDIG-EASL FONLIVER cohort